Somatic mutations of IDH1 have been frequently identified in many types of cancer, including approximately 80% of grade II-III gliomas, nearly 45% of secondary glioblastoma multiforme (GBM), and 33%-50% of adult primitive neuroectodermal tumors (Dang et al., 2009; Wang et al., 2013). This evidence concerns the gene IDH1 and glioblastoma.